1. THE ROLE OF THE PATHOLOGIST IN TARGETED THERAPY & PERSONALIZED MEDICINE Dr Dinah Parums, Principal Pathologist, 2007 2. WHAT ARE THE COMPONENTS OF A PATHOLOGY CAPABILITY…

Slide 1©2004 Millennium Pharmaceuticals, Inc. © 2004 Millennium Pharmaceuticals Inc. Opportunities and Challenges in Utilizing Biomarkers for Drug Development Mark Chang,…

1. Construction of Biomedical Database ApplicationsCase Study:Laboratory Assistant Suite 2. PlayersStarting May 2011, LAS stems from the joined efforts of IRCC and the Politecnico…

Leptomeningeal metastasis in solid tumors Leptomeningeal metastasis in solid tumors Joydeep ghosh Introduction.. Incidence: Symptomatic: 5% Asymptomatic: 20% Relative contributions:…

Slide 1 The Therapeutic Implications of EML4/ALK, ROS-1 and Other New Biomarkers Lyudmila Bazhenova, MD Associate Clinical Professor Lung Cancer Unit Leader UC San Diego…

Slide 1 April 9, 2011 Diagnostic Molecular Pathology Update Christopher D. Gocke, M.D. Associate Professor of Pathology & Oncology Johns Hopkins Medical Institutions…

Slide 1 EGFR Inhibitors in Colorectal Cancer John L. Marshall, MD Lombardi Comprehensive Cancer Center Slide 2 EGF TGF  Ligand Binding Phosphorylation and Activation Dimerization…

Slide 1 Jennie Bell CMGS/ACC Spring meeting 14 th April 2010 Slide 2 Slide 3  Cancer cells acquire the capacity for autonomous and dysregulated proliferation Uncontrolled…

What Kind of Rash Is It? A Tutorial About a Skin Rash Associated with Epidermal Growth Factor Receptor Inhibitors used in Cancer Treatment Denise Portz RN, BSN, OCN Alverno…

Predictive Biomarkers of EGFR Targeted Therapy: Beyond KRAS Josep Tabernero, MD PhD Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO) Barcelona,…